HOUSTON- LAWFUEL – Press Release Service –Aug. 24, 2006–CytoGenix,…

HOUSTON- LAWFUEL – Press Release Service –Aug. 24, 2006–CytoGenix, Inc. (OTCBB:CYGX) announced today that it has filed a patent application entitled “Single Stranded Expression Systems for Cancer Genetics and Other Applications” with the US Patent and Trademark Office.

The patent application is based on the results of recent experiments published in the journal Clinical Cancer Research by the inventors, CytoGenix’ Chief Scientific Officer, Dr. Yin Chen and CytoGenix director and scientific advisor, Dr. Cy A. Stein, Professor of Medicine at Albert Einstein College of Medicine and Montefiore Medical Center. These experiments show that the company’s proprietary ssDNA technology effectively combats some types of tumor growth and can be used to silence cancer genes.

Dr. Malcolm Skolnick, CytoGenix, Inc. CEO commented, “This is another example of the robust regulatory activity of CytoGenix’ ssDNA expression technology. This patent application seeks protection for use of this technology in cancer treatment, in parallel with our patent applications filed for use of the ssDNA technology in antiviral, anti-inflammatory and antibacterial applications.”

About CytoGenix: CytoGenix, Inc.CytoGenix, Inc. is a Houston-based biopharmaceutical company that develops and markets innovative products and services based on its proprietary ssDNA expression technology. The company has developed a breakthrough synthetic process for large-scale production of high purity DNA at a fraction of the cost of traditional fermentation methods. CytoGenix is the recipient of the 2006 Frost & Sullivan Technology Innovation award for biotechnology processing, and has one issued US patent and 43 international or US pending patent applications claiming methods and materials in connection with these platform technologies.

SAFE HARBOR: Except for statements of historical fact, the statements in this press release are forward-looking. Such statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include, but are not limited to, general economic conditions, risks associated with the acceptance of new products, competition, and other factors more fully detailed in the company’s filings with the Securities and Exchange Commission. Additional information about CytoGenix and its technology is found on the website at www.cytogenix.com.

Scroll to Top